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ABSTRACT 
Epithelial–mesenchymal transition (EMT) has been associated with increased aggressiveness and 
acquisition of migratory properties providing tumor cells with the ability to invade into adjacent 
tissues. Downregulation of E-cadherin, a hallmark of EMT, is mediated by several transcription 
factors (EMT-TFs) that act also as EMT inducers; among them, Snail1 and the bHLH transcription 
factor E47. We previously described lysyl oxidase-like 2 (LOXL2), a member of the lysyl oxidase 
family, as a Snail1 regulator and EMT inducer. Here we show that LOXL2 is also an E47 interacting 
partner and functionally collaborates in the repression of E-cadherin promoter. Loss and gain of 
function analyses combined with in vivo studies in syngeneic breast cancer models demonstrates 
the participation of LOXL2 and E47 in tumor growth and their requirement for lung metastasis. 
Furthermore, LOXL2 and E47 contribute to early steps of metastatic colonization by cell and non-
cell autonomous functions regulating the recruitment of bone marrow progenitor cells to the 
lungs and by direct transcriptional regulation of fibronectin and cytokines TNFα, ANG-1, and GM-
CSF. Moreover, fibronectin and GM-CSF proved to be necessary for LOXL2/E47 mediated 
modulation of tumor growth and lung metastasis. 
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Introduction 
Epithelial–Mesenchymal transition (EMT), an essential process in development, has been 
established as a key event for early metastatic stages. It provides tumor cells with the ability to 
invade into adjacent tissues and to promote their intravasation and extravasation (1-3). 
Downregulation of E-cadherin is a hallmark of EMT, leading to the loss of cell-cell interactions and 
apical–basal cell polarity required for the acquisition of a motile and invasive cell behavior (1, 4). 
Several transcription factors have been described as EMT inducers, including members of the 
Snail, bHLH and ZEB families (EMT-TFs) (5, 6). Among the bHLH factors, E47 (encoded by the E2A 
gene) is an EMT-TF (7-9). 
EMT-TFs are regulated at both transcriptional and post-transcriptional levels, including miRNAs 
and post-translational regulatory mechanisms that impinge on the stability, nuclear localization 
and/or functional activity (6, 10). Lysyl oxidase-like 2 (LOXL2) regulates Snail1 stability, and 
contributes to EMT induction by Snail1-dependent and -independent mechanisms (11-13). LOXL2 
is a member of the lysyl oxidase (LOX) family, constituted by the prototypical LOX and four related 
members (LOXL1-4) (14) sharing a conserved catalytic domain required for the oxidative 
deamination of peptidyl-lysine residues in substrates generating covalent inter- and 
intramolecular crosslinks during extracellular matrix assembly (14-16). Most of the LOX family 
members have also been implicated in tumorigenesis (17). LOXL2 has been shown to be involved 
in invasion of breast carcinoma and associated to poor clinical outcome and metastasis in (N0) 
and ER(-) breast tumors (13, 18, 19). Intracellular accumulation of LOXL2 is a prognostic marker in 
head and neck squamous cell carcinomas (12) and is associated to distant metastasis of basal 
breast carcinoma (13). However, little is known about LOXL2 functions in early metastatic events. 
Pre-metastatic niche formation is an essential event for early tumor cell homing and eventual 
colonization of secondary organs (20). It involves a complex network of tumor-host interactions, 
4 
 
secretion of soluble factors and exosomes that mediate the remodeling of the extracellular matrix 
and the recruitment of bone marrow derived cells (BMDC) into target organs (20-22). Secreted 
LOX and hypoxia are relevant to metastasis and pre-metastatic niche formation in breast cancer 
(23, 24) and hypoxia-induced LOXL2 and LOXL4 also contribute to the recruitment of BMDC by 
specific breast carcinoma cells (25). 
Results we describe here demonstrate that LOXL2 interacts with E47 to collaborate in down-
regulation of E-cadherin transcription. We also show that interference with either factors 
decreases the metastatic potential of highly malignant breast cancer cells concomitant with a 
marked reduction in the mobilization and recruitment of bone marrow progenitor cells (BMPC) to 
pre-metastatic sites. Furthermore, LOXL2 and E47 downregulation impairs transcriptional 
expression of fibronectin and multiple cytokines at primary tumors and/or metastatic lungs. 
Noticeably, LOXL2 or E47 actions in these processes depend on fibronectin and GM-GSF but are 
independent of other LOX members, thus demonstrating novel and specific functions for LOXL2 
and E47 proteins in breast cancer metastasis. 
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RESULTS 
 
E47 and LOXL2 interact and collaborate in E-cadherin promoter repression  
In order to identify partner(s) interacting with E47, we performed a two-hybrid screen resulting in 
the identification of LOXL2 (data not shown). Co-immunoprecipitation assays in stable MDCK-
EGFP-E47 cells (9) transiently transfected with LOXL2-Flag indicated that LOXL2 and E47 interact in 
vivo (Figure 1a). In vitro pull-down assays confirmed interaction between GST-E47 and LOXL2-Flag 
(Figure 1b). Immunofluorescence analysis showed that LOXL2 co-localizes with E47 in the 
perinuclear region (Figure 1c), as reported for LOXL2 and Snail1 (11). Importantly, interaction of 
endogenous LOXL2 and E47 proteins was confirmed by co-immunoprecipitation in two breast 
carcinoma cell lines, mouse Eo771 and human MDA-MB231 cells (Figure 1d). 
As we have recently observed that E47 induced a dose dependent repression of E-cadherin 
promoter activity (9), we tested the functional consequence of LOXL2/E47 interaction on the 
regulation of the E-cadherin promoter. Interestingly, E47-mediated repression was increased by 
50% in the presence of LOXL2 (Figure 1e), indicating that E47 and LOXL2 collaborate in E-cadherin 
repression, similar to Snail1 and LOXL2 (11), in full agreement with the binding of both factors to 
the endogenous E-cadherin promoter (9, 26). Accordingly, E-cadherin is not detected in cells 
expressing LOXL2 and E47 (Figure 1c). Deletion of the AD1 transactivation domain of E47 
(E47ΔAD1 mutant), required for recruitment of co-factors (27), abolished E-cadherin promoter 
repression, but co-transfection of LOXL2 with E47ΔAD1 restored promoter repression (Figure 1e). 
The collaboration between LOXL2 and E47 proved to be also independent of LOXL2 catalytic 
activity (Figure 1f).  
These data indicate that E47 and LOXL2 interact and collaborate in the repression of the E-
cadherin promoter independently of the E47 AD1 domain and LOXL2 catalytic activity. 
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E47 or LOXL2 silencing influences the expression of EMT markers and some of the LOX members 
The implication of some EMT-TFs as well as LOXL2 in breast cancer models (3, 5, 18) and 
association of E2A expression in N0 breast carcinomas (9) has been previously shown. To explore 
the significance of E47 and LOXL2 in breast cancer, we analyzed their expression in two syngeneic 
mouse breast carcinoma models, Eo771 and 4T1 cells. Mesenchymal Eo771 cells, derived from 
C57BL/6J breast carcinoma (28), express both E47 and LOXL2, while epithelial 4T1 cells, derived 
from Balb/C breast carcinoma, only express E47 and maintain E-cadherin expression 
(Supplementary Figure S1). 
To examine the role of E47 and LOXL2, we first generated Eo771 cells stably expressing mCherry 
and Luciferase (Eo771mCherryLuc) in which LOXL2 or E47 were stably silenced. We selected two 
short hairpin RNA sequences against E47 (shE47) and LOXL2 (shLOXL2) and stable derived pools 
and clones for further analysis showing 60-80% decrease in E47 or LOXL2 expression 
(Supplementary Figure S2). While LOXL2 silencing did not influence E47 expression, E47 silencing 
induced a decrease of LOXL2 protein (Supplementary Figure S2a and b), suggesting the 
involvement of post-transcriptional regulation.  
Analysis of EMT markers showed that E47 knockdown in Eo771 cells decreased Snail2 and ZEB1 
expression but LOXL2 silencing did not affect the expression of those EMT-TFs (Supplementary 
Figure S2b). No expression of Snail1 was observed in Eo771 cells. Both shE47 and shLOXL2 cells 
exhibited a strong decrease in fibronectin expression, but no change in E-cadherin expression 
(Supplementary Figure S2a and b) and maintained a mesenchymal-like phenotype (not shown). 
We further tested for any expression change of LOX members. Eo771-shE47 cells displayed LOX 
upregulation, and shLOXL2 cells showed LOX and LOXL3 upregulation, but no significant 
differences in LOXL1 or LOXL4 transcripts (Supplementary Figure S3a). Upregulation of LOXL3 
protein levels resulting from either LOXL2 or E47 silencing was confirmed both in cell extracts and 
conditioned media, and a slight increase was observed in secreted LOX protein after E47 silencing 
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(Supplementary Figure S3b and c). Interestingly, LOXL2 was not detected in the conditioned 
media from parental Eo771 cells nor any of the derived clones (Supplementary Figure S3c), 
suggesting that Eo771 cells do not secrete LOXL2 as confirmed in conditioned media from 
transiently transfected Eo771 cells in which LOXL2-HA was barely detected (Supplemental Figure 
S3d). These data show that LOXL2 or E47 silencing in Eo771 cells induces the expression of LOXL3 
and/or LOX and the decrease of EMT markers fibronectin, Snail2 or ZEB1, without apparent effect 
on the phenotype. 
 
E47 or LOXL2 silencing reduces tumor growth and decreases lung metastasis.  
To investigate the role of E47 and LOXL2 in the tumorigenic and metastatic behavior of Eo771 
cells, spontaneous metastasis assays were performed in syngeneic mice. Eo771 parental, shE47, 
shLOXL2 and control cells were injected into the mammary fat pad (mfp) of C57BL/6J mice. 
Tumors started to develop 7 days post-injection (dpi) in all groups but those derived from shE47 
and shLOXL2 cells grew more slowly than controls (Figure 2a and b; Supplementary Figure S4a and 
b). Since no differences in tumor growth or histology were found between the two control groups, 
pGIPZ and pLKO (data not shown), we refer most of the following analyses to pLKO control. 
Histological analysis of tumors showed that parental and pLKO cells induce undifferentiated 
tumors with loose intercellular contacts and little stromal component, and silencing of LOXL2 or 
E47 did not significantly change tumor histology (Figure 2c, left panels). Analysis of mice at 
necropsy 24 dpi showed spontaneous lung metastasis reduced to 90% in Eo771-shLOXL2 and 55% 
in -shE47 injected mice (Figure 2d and e; Supplementary Figure S4c). Histological lung analyses 
demonstrated that macrometastases where only detected in control cells (Figure 2c, right panels, 
and data not shown). Similar results were obtained in experimental metastasis assays (tail vein 
injection) where lung metastatic lesions were reduced 95% and 75% in Eo771shLOXL2- and shE47-
injected mice, respectively (Figure 2f and g). Together, these data indicate that E47 and LOXL2 are 
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required for lung metastasis of Eo771 cells independently of their tumor growth suppressive 
effects. To further analyze the LOXL2/E47 collaboration, and because of the inability to obtain 
double knockdown cells due to cell viability, a rescue experiment was performed overexpressing 
LOXL2 in Eo771-shE47 cells (Supplementary Figure S2d). LOXL2 expression did not significantly 
change tumor growth, histology, or metastatic burden (Figure 2h-j), suggesting that both factors 
are jointly required for Eo771 tumorigenenic and metastatic potential. To confirm the 
collaboration of LOXL2 and E47 in and independent model, similar studies were performed in 4T1 
cells. Because these cells only express E47 (Supplementary Figure S1) a double approach was 
followed: knockdown of E47 and overexpression of LOXL2. E47 silencing in 4T1 cells did not 
change E-cadherin or Snail1/2 expression while LOXL2 expression modestly decreased E-cadherin 
expression (Figure 3a and g). Injection of manipulated 4T1 cells in syngeneic Balb/C mice indicated 
that E47 depletion strongly decreased tumor growth and lung metastasis (Figure 3 b-f) while 
overexpression of LOXL2 did not significantly affect tumor growth or metastatic burden as 
determined by bioluminescence (Figure 3h-j), but increased the size of lung metastasis compared 
to controls (Figure 3f). No changes in tumor histology were observed after manipulation of either 
E47 or LOXL2 in 4T1 cells (Figure 3f, lower panels). These data support the collaboration of LOXL2 
and E47 in promoting an aggressive phenotype in breast cancer cells.  
 
LOXL2 and E47 are required for early metastatic colonization  
To explore the mechanisms involved in metastatic suppression by E47 and LOXL2 silencing, we 
studied the implication of these proteins in metastatic niche formation and early stages of 
metastasis. Towards this aim, we first analyzed the recruitment of BMDC to metastatic organs in 
the Eo771 model using GFP bone marrow transplanted C57BL/6J mice (21). Parental Eo771, pLKO, 
shE47 and shLOXL2 cells were injected into the mfp and mice where sacrificed 15 dpi when Eo771 
tumor cells were first detected in lungs (Supplementary Figure S5). Lungs were analyzed for 
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BMDC-GFP+ infiltration and the presence of metastatic Eo771-mCherry+ cells.  About 10% of GFP+ 
cells were recruited to the lungs of non-injected mice (Figure 4b). Lungs of mice carrying parental 
Eo771 or Eo771-pLKO tumors showed a 7-10 fold increase in the infiltrated BMDC-GFP+ and 
contained clusters of metastatic mCherry+ cells co-localizing with GFP+ cells (Figure 4a, panels a-f, 
4b and c). In lungs from mice bearing shLOXL2 or shE47 tumors BMDC-GFP+ infiltration regressed 
to basal levels (Figure 4a, panels g-l, 4b and c). We then analyzed the BMDC populations mobilized 
to the blood and recruited to the lungs and the primary tumors of C57BL/6J mice injected with 
Eo771 interfered cells at 15 dpi. We focused on bone marrow progenitor (BMPC, c-kit+/Sca-1+) 
and myeloid cell populations (CD11b+/Gr1+) because of their reported involvement in pre-
metastatic niche formation (21, 29). We first tested whether the inhibitory effects of GFP on the 
immune response of 4T1 cells in Balb/C mice (30) could affect Eo771 cells, since shLOXL2 was 
cloned into pGIPZ-GFP vector. Both myeloid and BMPC populations increased in blood and lungs 
of C57BL/6J mice injected with Eo771-pLKO and -pGIPZ cells compared to non-injected cells, with 
no significant differences between the two groups (Supplementary Figure S6); thus we used pLKO 
cells as controls in subsequent analyses. Silencing of LOXL2 or E47 in Eo771 cells affect neither 
myeloid cell mobilization nor their lung recruitment (Figure 5a and b). In contrast, BMPC 
mobilized to the blood were reduced in mice bearing Eo771-shLOXL2 or shE47 tumors (Figure 5d). 
Moreover, BMPC levels in the lungs of Eo771-shLOXL2 or shE47 mice were similar to non-injected 
mice (Figure 5e). Noticeably, LOXL2 expression in Eo771-shE47 cells increased BMPC lung 
recruitment to levels similar to pLKO control cells without altering myeloid cell recruitment 
(Figure 5c and f). Similar findings were obtained in 4T1-LOXL2 cells where the BMPC population 
increased in blood and lungs of Balb/C-injected mice without modification in the myeloid 
population (Figure 5i, j, m and n); an apparent reverse situation was found in 4T1-shE47-bearing 
mice showing a significant decrease of myeloid cells and increased BMPC in lungs without changes 
in blood mobilization of either population (Figure 5g, h, k and l). No significant differences in 
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myeloid cells or BMPCs recruitment to primary tumors were detected among the different groups 
and controls (Supplementary Figures S6 and S7).  
These data indicate that LOXL2 and/or E47 are required for the mobilization and lung recruitment 
of different populations of bone marrow-derived cells dependent on the specific metastatic 
microenvironment.  
 
LOXL2 and E47 modulate the expression of fibronectin and cytokines during formation of the 
metastatic niche 
Fibronectin, LOX and various cytokines have been previously implicated in pre-metastatic niche 
formation (20-22, 29, 31). We therefore studied the influence of LOXL2 and E47 on the expression 
of these factors during early metastatic stages. We first performed qPCR analysis in the primary 
tumors and lungs of mice injected with Eo771-pLKO, shLOXL2 and shE47 cells at 15 and 24 dpi 
(early colonization and end-point of the experiment, respectively; Supplementary Figure S5). 
Silencing of E47 and LOXL2 in primary tumors at both time points was confirmed (Figure 6a; 
Supplementary Figure S8a and b). Both LOXL2 and E47 levels were decreased in Eo771-shE47 and 
shLOXL2 tumors, suggesting a crosstalk between these two factors within the tumor context. In 
the lungs, no significant differences in LOXL2 expression were observed in different groups at 15 
dpi (Figure 6b), indicating the probable contribution of stromal LOXL2. However, very low levels of 
LOXL2 were detected in the lungs of mice bearing Eo771-shLOXL2 or shE47 tumors 24 dpi 
(Supplementary Figure S8c). Upregulation of LOX and/or LOXL3 was also detected in primary 
tumors and lungs of Eo771-shE47 or shLOXL2 mice at 15 and 24 dpi without changes in LOXL1 or 
LOXL4 expression (Figure 6a and b; Supplementary Figure S8b and c), as observed in cell cultures 
(Figure S3a).  
Fibronectin expression was strongly decreased in tumors and lungs of Eo771-shLOXL2 or shE47 
mice (Figure 6a and b; Supplementary Figure S8a and c) as compared to controls. Overexpression 
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of LOXL2 in Eo771-shE47 cells did not significantly modify the expression of fibronectin or of other 
LOX member (Figure 6c and data not shown). However, in the lungs of Balb/C mice bearing 4T1-
LOXL2 cells, increased fibronectin expression as well as E47, LOXL1, and LOXL3 was detected 
mainly (Figure 6d). In contrast, although decreased LOXL1 and LOXL2 was found in tumors of 4T1-
shE47 mice, increased expression of all LOX members was detected in lungs (Supplementary 
Figure S9), suggesting a more complex regulation in the absence of both E47 and LOXL2.  
To identify the cytokines involved, we first tested the conditioned media from Eo771-interfered 
cells in a cytokine array. Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF) and 
Angiopoietin-1 (ANG-1) were decreased in the conditioned media from both Eo771-shLOXL2 and 
shE47 cells (Figure 7a). The down-regulation of GM-CSF and ANG-1 was confirmed by qPCR in 
cultured cells, primary tumors, and lungs from Eo771-shE47/shLOXL2-injected mice at 15 and 24 
dpi (Figure 7b-d; Supplementary Figure S8d and e). We also analyzed the expression of cytokines 
previously related to the recruitment of BMDC and pre-metastatic niche formation, Transforming 
Growth Factor β (TGFβ), Tumor Necrosis Factor α (TNFα), S100A8/S100A9 and tenascin-C (TEN-C) 
(29, 31, 32). E47 or LOXL2 silencing induced a marked decrease in TNFα expression in Eo771 cells, 
tumors and lungs (15 and 24 dpi) while no differences were detected for TGFβ and TEN-C 
expression (Figure 7b-d; Supplementary Figure S8d and e). Additionally, S100A8/S100A9 
expression was strongly downregulated in lungs from Eo771-shLOXL2 or shE47-injected mice 
(Figure 7d; Supplementary Figure S8f). Lung expression of TNFα, GM-CSF and ANG-1 was restored 
to varying levels after LOXL2 overexpression in Eo771shE47 cells (Figure 7e). Similar analyses in 
Balb/C mice injected with 4T1 cells manipulated for LOXL2 or E47 expression indicated the 
contribution of LOXL2 and E47 to cytokine expression; strong upregulation of GM-CSF and 
downregulation of S100A8/S100A9 levels were detected in lungs from 4T1-LOXL2 (Figure 7f) and 
4T1-shE47-injected mice, respectively, although upregulation of GM-CSF was also observed in 
4T1-shE47 cells (Supplementary Figure S9c).   
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The LOXL2 and E47 regulation of some cytokines was further explored at promoter level in the 
Eo771 system. The activity of TNFα and GM-CSF promoters was strongly decreased in Eo771-
shLOXL2 and shE47 cells in the absence and presence of PMA (a TNFα inducer) (Figure 7g and i) 
supporting transcriptional regulation. Indeed, transient assays in Eo771 cells indicated that E47 
upregulated the TNFα promoter in a dose-dependent fashion; although LOXL2 alone had no 
effect, together with E47 it induced a synergistic activation of the TNFα promoter (Figure 7h). 
Analyses of the GM-CSF promoter showed that LOXL2 induced a significant upregulation while 
E47 did not modify promoter activity in the absence or presence of LOXL2 (Figure 7j).  
Together, these data demonstrate that LOXL2 and E47 transcriptionally regulate the expression of 
fibronectin, GM-CSF, TNFα, ANG-1 and/or S100A8/S100A9 in primary tumors and metastatic lungs 
of breast carcinoma models. 
 
LOXL2 and E47 take over pre-metastatic niche conditioning and depend on fibronectin and GM-
CSF. 
We next analyzed whether the pro-metastatic actions of LOXL2 and E47 depend on a pre-
metastatic niche conditioning (21, 29). To this end, shE47 and shLOXL2-Eo771-mCherryLuc cells 
were tail vein injected in mice-bearing Eo771 tumors at 10 dpi when a pre-metastatic niche has 
been prepared in this system (Supplementary Figure S5) and lung metastasis analyzed 15 days 
later. Silencing of E47 or LOXL2 decreased metastasis burden by 65% and 85%, respectively 
(Figure 8a and b), indicating a predominant cell autonomous action of LOXL2 and E47 in 
metastatic colonization.  
Finally, the functional contribution of fibronectin and some of the cytokines regulated by 
LOXL2/E47 was also analyzed. Knockdown of fibronectin in Eo771 cells did not affect tumor 
growth (data not shown) but significantly reduced lung metastasis (>90%) and GM-CSF and TNFα 
expression in lungs (Figure 8c-f). On the other hand, GM-CSF silencing strongly reduced tumor 
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growth and lung metastasis, associated to decreased fibronectin but increased TNFα expression 
(Figure 8g-k). No significant changes in lung recruitment of BMPC or myeloid cells were detected 
in Eo771-shGM-CSF bearing mice (Figure 8l), suggesting that GM-CSF is dispensable for BMDC 
recruitment and might contribute to metastasis through fibronectin regulation. 
Altogether, the present data highlight the contribution of LOXL2 and E47 to early metastatic 
colonization by regulating fibronectin and pre-metastatic cytokines expression. 
 
DISCUSSION 
There is currently little information on E47 interacting partners that regulate its activity. Using an 
unbiased screening approach, we identified LOXL2 as an E47 partner. Our data demonstrate the 
E47/LOXL2 interaction and identify a new functional cooperation between both factors in the 
regulation of E-cadherin repression. We have partly uncovered the mechanism involved in LOXL2 
and E47 co-repression as independent of E47-AD1 domain and LOXL2 catalytic activity that 
suggest non-conventional mechanisms we are presently investigating. The recently reported 
binding of both factors to the endogenous E-cadherin promoter (9, 26) support their functional 
co-operation here described. Together with the previously identified Snail1-LOXL2 interaction 
(11), the present findings indicate that LOXL2 is an important regulator of several EMT-TFs, 
further corroborating the intracellular role of LOXL2 (11-13).  
Our data suggest that E47 and LOXL2 can play differential roles regarding E-cadherin repression 
and EMT induction in distinct cellular context. Thus, LOXL2 or E47 silencing in Eo771 cells 
decreases fibronectin and Snail2/ZEB1 without inducing E-cadherin expression while 
overexpression of LOXL2 in 4T1 cells moderately decreases E-cadherin expression. Nevertheless 
these changes are insufficient to modify the Eo771-mesenchymal or 4T1-epithelial phenotypes, in 
contrast to other systems, including basal carcinoma cells (9, 11-13), and might be determined by 
the complementary action of other EMT-TFs in different cellular contexts.  
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Interestingly, we observed an apparent cross-regulation between E47 and LOXL2 that seems to be 
influenced by the tumor context, where E47 and LOXL2 could act synergistically in tumor growth 
and metastasis dissemination as demonstrated in two breast cancer models. Indeed, silencing of 
LOXL2 or E47 in Eo771 cells induces a mutual downregulation of both factors in tumors, and 
LOXL2 overexpression in 4T1 cells induces E47 in metastatic lungs. In fact, initial E2A and LOXL2 
promoter analyses support transcriptional cross-regulation by LOXL2 and E47 that deserve further 
studies (EP Cuevas, unpublished data). LOXL2 participation in lung metastasis dissemination in 
gastric (33) and breast carcinomas (13, 17, 34) has been associated to extracellular LOXL2. Our 
results support a new scenario where LOXL2 executes its functions intracellularly since Eo771 cells 
do not secrete LOXL2 (Supplementary Figure S3), in agreement with our previous studies (11-13). 
The coordinated action of LOXL2 and E47 in the development of experimental lung metastasis 
suggests cell-autonomous actions for both factors in lung homing/colonization even in the 
absence of primary tumors. In fact, LOXL2 and E47 action on metastasis seems to prevail over pre-
metastatic niche conditioning supporting a cell-autonomous action of both molecules in early 
metastasis colonization. Recent data have revealed the requirement of mesenchymal-epithelial 
transition (MET) for metastasis outgrowth (35-37). Our data suggest that EMT-like processes 
mediated by LOXL2 and E47 could be a requirement for early metastastic stages before overt 
macrometastasis appear. This proposal is nevertheless compatible with additional actions of both 
factors on the metastatic microenvironment. Indeed, the present data show that E47 and/or 
LOXL2 are needed for the recruitment of BMPC at early metastatic sites. Interestingly, in both 
Eo771 and 4T1 breast models, BMPC (ckit+/Sca1+) is the main recruited population compared to 
myeloid CD11b+/Gr-1+ population in response to LOXL2 expression. In fact, myeloid cells were 
mobilized to the blood and recruited to the lungs in mice bearing Eo771-shLOXL2 and -shE47 
tumors as well as in 4T1-LOXL2 tumors. Nevertheless, myeloid cell recruitment decreased after 
E47 deletion in 4T1 cells, suggesting that, in the absence of LOXL2, E47 might primarily impact on 
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myeloid population on a Balb/C background. Our data thus suggest that LOXL2 and/or E47 are 
implicated in the recruitment of the more undifferentiated BMPC population, in agreement with 
previous reports (21), or myeloid populations (38, 39) depending of the specific metastasis 
microenvironment. Interestingly, LOXL2 and E47 regulate fibronectin expression in Eo771 cells, as 
well as in tumors and early metastatic lungs. This finding is relevant, as BMPC are preferentially 
recruited to lung areas rich in fibronectin (21), furthermore, a fibronectin-enriched extracellular 
matrix provides a favorable environment for LOX catalytic activity in the pre-metastatic niche (24, 
40, 41). Indeed, fibronectin regulation by LOXL2 and E47 seems to be determinant for breast 
cancer metastatic fitness as indicated by fibronectin knockdown in Eo771 cells. Interestingly, 
silencing of LOXL2 or E47 induces the upregulation of LOX and LOXL3 at Eo771 primary tumors 
and early metastatic sites (Figure 6) that could partly explain the myeloid cells recruitment as 
reported in other breast models (24). Importantly, LOX upregulation and myeloid cell recruitment 
do not compensate for the absence of LOXL2 or E47 for development of micrometastases, 
indicating a dominant role for these proteins at early metastatic stages. Preliminary analyses of 
Eo771-tumor extracellular matrix suggest no major changes in collagen deposition or organization 
in response to E47 and LOXL2 silencing or overexpression (data not shown). We therefore 
postulate that an E47/LOXL2-dependent mechanism is involved in fibronectin deposition and 
BMPC recruitment to early metastatic sites, while LOX-dependent mechanisms would execute 
myeloid cell recruitment and cross-linking of extracellular matrix in specific metastasis 
microenvironments. The present results indicate that LOXL2 and E47 also regulate the expression 
of GM-CSF, TNFα and ANG-1, in primary tumor and lungs, factors that contribute to BMDC 
recruitment and pre-metastatic niche (20, 21). The transcriptional downregulation of TNFα and 
GM-CSF promoters by LOXL2 and E47 in Eo771 cells, together with inhibition of metastasis 
colonization following GM-CSF knockdown might well explain the remarkable effect of both 
factors in early metastatic colonization, further reinforcing the intracellular action of LOXL2. 
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Interestingly, GM-CSF knockdown strongly suppressed fibronectin expression in lungs without 
affecting BMPC recruitment. In contrast, a marked decrease in GM-CSF and TNFα expression 
occurs after fibronectin silencing, suggesting a coordinated action of LOXL2/E47 in the regulation 
of fibronectin through GM-CSF. Interestingly, LOXL2 or E47 silencing also dramatically reduced 
S100A8/S100A9 expression in lungs, indicating that at least in Eo771 and 4T1 models these 
cytokines could be involved in the recruitment of BMDC at early metastatic sites.  
The present results extend recent data from Wong et al. reporting that under hypoxia, secreted 
LOXL2 in human breast cancer cells induce BMDC lung infiltration and colonization of metastatic 
cells by influencing the extracellular matrix (25). Moreover, our results support novel cell-
autonomous actions of LOXL2 and suggest that high levels of LOXL2 as those present in Eo771 
cells or in human basal-like carcinoma cells (13) can be sufficient to promote early metastasis 
colonization. Noticeably, high LOXL2 levels in breast carcinoma cells associate to a mesenchymal 
phenotype (13, present data), further suggesting that EMT mediated by LOXL2 favors initial lung 
homing and can over-impose on pre-metastatic niche formation. This scenario, together with the 
upregulation of E47 observed in primary N0 breast carcinomas (9) provides additional 
mechanisms for metastasis progression in breast tumors. 
 
 
MATERIALS AND METHODS 
 
Cell culture  
Human HEK293T and MDA-MB-231, dog MDCK, and mouse Eo771 and 4T1 cell lines were 
obtained from the American Type Culture Collection. MDCK-EGFP-E47 and MDCK-LOXL2-Flag cells 
were previously described (9, 11). Eo771-mCherryLuc and 4T1-mCherryLuc cells were obtained by 
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lentiviral infection with PRRL-cPTT-PGK-mCherry-W vector. All cell lines were grown according to 
American Type Culture Collection specifications. 
 
Vectors 
Mouse pcDNA3-E47, human pReceiver-LOXL2-HA and mouse pcDNA3-LOXL2-Flag and LOXL2-
ΔCat-Flag vectors have been previously described (9, 13, 26). pZeo-E47 vector was obtained by 
subcloning mouse E47 cDNA into the pZeo vector, from which the pZeo-ΔAD1-E47 vector was 
generated by deletion of nt 1 to 279 (a.a. 1-93). 
 
Two-hybrid screen.  
The two-hybrid screen was performed as described (7) using the bHLH domain of E47 as bait. One 
of the isolated prays corresponded to the cDNA sequence of LOXL2 catalytic domain. 
 
RNA interference.  
Selected shRNAs sequences were:  TRCN00002-33414 and TRCN0000233416 for mouse E47; and 
TRCN0000054618 and TRCN0000054619 for mouse GM-CSF (Sigma-Aldrich); sc-35371-V for 
mouse fibronectin (Santa Cruz Biotechnology, Inc.); and V3LMM_455747 for mouse LOXL2 (Open 
Biosystem. Controls pLKO and pGIPZ were from Sigma-Aldrich and Open Biosystem, respectively. 
Stable transfectants were selected with 3 µg/mL puromycin for 2-3 weeks. At least two 
independent pools and/or clones were isolated from each transfection and used for further 
analysis. 
 
Transient transfections.  
Transfections were performed with Lipofectamine 2000 (Life Technologies) following 
manufacturer’s instructions.  
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Co-immunoprecipations, pull down assays and Western-Blot.  
Cell extracts were obtained using IPH buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 
0.5% NP-40) supplemented with proteases and phosphatases inhibitors (2mM PMSF, 2 μg/ml 
leupeptin, 20 ng/ml aprotinin, 1 mM sodium orthovanadate). Co-immunoprecipitations and pull-
downs assays were performed as described (9, 11) and blots were incubated with the indicated 
primary and secondary-HRP-conjugated antibodies (listed in Supplementary Table S1). 
 
Promoter analysis.  
Mouse E-cadherin promoter assays were performed as described (26, 42).  For TNFα and GM-CSF 
promoters, Eo771 cells and derived sh-clones were transiently transfected with mouse TNFα-
luciferase construct (pGL3-mTNF) (provided by Dr. M. Fresno, CBMSO, Madrid, Spain) or mouse 
GM-CSF-luciferase construct (pMGM0.2-luc) (provided by Dr. PN. Cockerill, St. James's University 
Hospital, Leeds, UK) and the indicated amounts of pcDNA3-LOXL2-Flag and/or pcDNA3-E47 
vectors, and co-transfected with 10 ng of CMV-βgal. When indicated, cells were treated with 100 
nM PMA 18h prior to lysis. 
 
Cytokine array.  
Secreted factors in conditioned media were detected using the mouse angiogenesis antibody 
proteome profiler array (#ARY015, R&D Systems), following manufacturer’s instructions.  
 
 
Semiquantitative and quantitative PCR studies.  
Total RNA from cell lines was extracted with Trizol (Life technologies) as described (42). Disruption 
of frozen tumors and lungs was performed also in Trizol using a politron device. Two micrograms 
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of RNA were treated with DNaseI and used for cDNA synthesis (42). Semiquantitative-PCR or 
quantitative-PCR were performed using pre-designed TaqMan© probes or SybrGreen PCR 
reagents (Sigma-Aldrich) on an iQ5 iCycler Realtime PCR Detection System (BioRad). Primers and 
probes sequences,and amplification conditions are indicated in Supplementary Tables S2 and S3. 
Relative expression was normalized to β-actin or GAPDH.  
 
Flow cytometry.  
Lung and primary tumor tissues were prepared as previously described (43). Peripheral blood was 
obtained by retro-orbital bleeding directly into anti-coagulant tubes. Cell suspensions were 
incubated with the following fluorescent primary antibodies (Supplementary Tables S1) for 45 min 
and fixed in 2% PFA over-night.  Fluorescence was measured using a FACSCalibur cytometer with 
CellQuest software (BD). FACS data were analyzed with FlowJo software (TreeStar). 
 
Immunofluorescence confocal microscopy.  
Immunofluorescence of cells fixed in 4% paraformaldehyde was performed as described (42). For 
tissue fluorescence, mice tissues were fixed overnight in 2% PFA:20% sucrose mix and 
cryoembedded in Tissue-tek OCT. Sections (5 μm) were stained with DAPI. GFP and mCherry-
positive cells were detected by their intrinsic signal. Fluorescent images were obtained using a 
Leica TCS-SP5 confocal microscope and analyzed using the Leica LAS-AF program. Digital images of 
mCherry/GFP stained sections were analyzed and pixels were quantified with ImageJ Software 
(NIH).  
 
Animal experimentation and in vivo imaging.  
For tumor induction and spontaneous metastasis assays, parental Eo771- and 4T1-mCherryLuc 
cells and derived clones were orthotopically injected (1x106 in 0.1 ml serum free growth medium) 
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into the left fifth mfp of 8 weeks-old C57BL/6J and Balb/C mice, respectively. Tumor growth was 
measured once a week by determination of the two orthogonal external diameters using a caliper 
and by bioluminescence. Tumors were surgically excised between 15 and 28 dpi. Bone marrow 
(BM) transplantation was performed as described (43). For experimental metastasis assays Eo771-
mCherryLuc cells and derived clones were injected (1x105 in 0.1 ml serum free growth medium) 
into the tail vein of 8 weeks-old C57BL/6J mice. Pre-conditioning experiments were performed as 
described (29); briefly, wild type Eo771 cells (without any labeling) were implanted into mfp of 
female 8-weeks C57BL/6J mice and 10 days later, Eo771pLKO-, shLOXL2-, or shE47--luciferase 
labeled cells were injected by tail. Lungs were removed for bioluminescence at 25 dpi of parental 
cell injection. 
 Live animal bioluminescence optical imaging was performed using the IVIS Spectrum system or 
the IVISR Lumina II system (Caliper, Xenogen) (13). At the end-point of the experiments, mice 
were euthanized 5 min later of in vivo bioluminiscent measure, and organs analyzed for luciferase 
expression. Data were quantified with the Living Imaging software 4.2 (Xenogen Corporation). 
Tissues were dissected, fixed in 10% formalin and embedded in parafim for hematoxylin/eosin 
staining, or snap-frozen in liquid nitrogen for RNA extraction. All mouse work was performed in 
accordance with institutional, IACCUC, AAALAS and UAM guidelines and approved by the 
corresponding Use Committee for Animal Care. 
 
Statistical analysis. 
Mouse experiments were performed in duplicate, using at 4-6 mice per treatment group. All the 
in vitro experiments were performed at least twice. Statistical analyses were carried out using 
Graph Pad Prism software and statistical significance was determined by ANOVA or two-tailed 
Student's t test.  
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Figure Legends 
Figure 1: LOXL2 functionally interacts with E47. (a) and (d) Coimmunoprecipitation assays in (a) 
MDCK-EGFP-E47 cells transiently transfected with LOXL2-Flag, or (d) MDA-MB231 and Eo771 cells. 
Cell extracts were immunoprecipitated with anti-EGFP, anti-Flag or anti-LOXL2 and analyzed by 
WB with anti-LOXL2 or anti-EGFP (a), anti-LOXL2 or anti-E2A antibodies (d). Left panels show input 
levels of indicated proteins. LOXL2-Flag, EGFP-E47, endogenous LOXL2 and E2A, and control IgG 
are indicated. Data show one representative experiment out of two. (b) Pull-down assay. HEK293T 
cells were transiently transfected with LOXL2-Flag and cell extracts incubated with GST-E47 or 
GST. LOXL2-Flag and GST-E47 proteins were detected by WB with anti-Flag and anti-GST 
antibodies, respectively. Left insert shows input LOXL2-Flag level. (c) Co-localization of 
endogenous E47 (E2A) with LOXL2-Flag in MDCK-LOXL2-Flag cells (upper, merged images) and E-
cadherin stain in parental MDCK and MDCK-LOXL2-Flag cells (bottom) analyzed by confocal 
immunofluorescence with anti-Flag, anti-E-cadherin (green) or anti-E2A antibodies (red). Nuclei 
stained with DAPI. Amplified image (upper right) shows LOXL2/E47 co-localization in the 
perinuclear region. Bar, 20 µm. (e) and (f) Activity of E-Cadherin promoter in HEK293T cells in the 
presence of wt-E47 or E47ΔAD1 (100 ng) and/or wt LOXL2-Flag or LOXL2ΔCD-Flag (50 ng). Activity 
(RLU) was normalized to control pcDNA3 vector. Results represent the mean +/- SD of at least 
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three independent experiments performed in triplicate samples. **0.001<p<0.005, ***p<0.001, 
ns=not significant. 
 
Figure 2: LOXL2 or E47 silencing in Eo771 cells reduces tumor growth and dramatically decreases 
lung metastasis. (a) Representative bioluminescence images of C57Bl/6j mice injected in the mfp 
with Eo771pLKO, shLOXL2 (clone #3) or shE47 (414pool) cells, at 7 and 15 dpi. (b) Primary tumor 
growth of Eo771pLKO, shLOXL2 or shE47 cells at the indicated dpi, assessed by tumor volume. n=6 
mice/group. (c) Histology of representative primary tumors (left) and lungs (right) from pLKO, 
shLOXL2#3 or shE47-416#4 Eo771 injected mice (x20) at 24 dpi, insets show amplified areas (x40). 
(d) Representative bioluminescence images of lungs and (e) quantification of total lung photon 
flux of Eo771pLKO, shLOXL2 or shE47 mfp injected mice at 24 dpi. n=6 mice/group. (f) 
Representative bioluminescence images of lungs and (g) quantification of total lung photon flux 5 
weeks after tail vein injection of Eo771pLKO, shLOXL2 or shE47 cells in C57BL/6J mice. n=6 
mice/group. (h) Representative bioluminescence images (15 dpi) and (i) primary tumor growth by 
volume of C57Bl/6 mice injected in the mfp with Eo771pLKO, shE47-416#4, and shE47-416#4 cells 
transfected with control pcDNA3 or LOXL2-HA. n= 4 mice/group. (j) Representative histological 
sections of lungs of C57Bl/6 mice injected in the mfp with the indicated Eo771 cells at 15 dpi. 
Asterisks indicated metastasis foci. Color scales represent the photon flux (photons per second) 
emitted from the tumor region (a and h) or dissected lungs (d and f). Data in (b, e, g,  and i) show 
the mean +/- SD. *p<0.05, **0.001<p<0.005, ***p<0.001, n.s., non-significant. 
 
Figure 3 Tumorigenic and lung metastatic behavior of 4T1 cells after E47 silencing or LOXL2 
overexpression. (a) and (g) Western blot analyses of E47, LOXL2 and the indicated markers in wt 
4T1 cells, and after E47 silencing (sh414 and sh416 pools) (a) or LOXL2 overexpression (g) and 
corresponding controls (pLKO and pcDNA3, respectively). (b) and (c) Bioluminescence images (21 
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dpi) (b) and primary tumor growth assessed by volume (c) of Balb/C mice injected in the mfp with 
control 4T1pLKO and shE47 (414 and 416 pools) cells. n=5 mice/group. (d) and (e) 
Bioluminescence images (d) and quantification of total lung photon flux (e) of lungs from Balb/C 
mice mfp injected with control 4T1pLKO and shE47 (414 and 416 pools) cells at 21 dpi. n=5 
mice/group. (f) Representative histological sections of primary tumors (left) and lungs (right) of 
Balb/C mice mfp injected with the indicated 4T1 controls and shE47 or LOXL2 overexpressing 
pools. Asterisks indicated metastasis foci. (h-j) Primary tumor growth assessed by volume (h), 
representative bioluminescence images of lungs (i) and quantification of total lung photon flux (j) 
from Balb/C mice injected in the mfp with control 4T1pcDNA3 and LOXL2-HA cells at 28 dpi. n=4 
mice/group. Color scales represent the photon flux (photons per second) emitted from the tumor 
region (b) or dissected lungs (d and i). Data in (c, e, h and j) show the mean +/-SD. *p<0.05, 
**0.001<p<0.005, n.s., non-significant. 
 
Figure 4: LOXL2 and E47 required for BMDCs recruitment to lung. (a)  Confocal analysis of BMDC-
eGFP+ (green) and Eo771 tumor mCherry+ cells (red) in the lungs. C57BL/6J mice were 
transplanted with eGFP+ BM cells, injected into the mfp with wt Eo771, pLKO, shLOXL2 (clones #3 
and #8) or shE47 (414pool and clone 416#4) cells and lungs analyzed 15 dpi. Nuclei were stained 
with DAPI. Representative images are shown for each experimental group. Bar, 100 µm. Amplified 
images are shown in the right panels.  (b) and (c) Quantification of the total number of BMDC-
GFP+ (green) (b) and metastatic mCherry+ cells (red) (c) per field area in each independent group, 
including non-injected mice (NI), n=3 mice/group. Data show the mean +/-SD. **0.001<p<0.005, 
***p<0.001 by ANOVA. 
 
Figure 5: LOXL2 and E47 are required for mobilization and lung recruitment of BMPC. FACS 
analysis and relative quantification of myeloid (CD11b+/Gr-1+) and BMPC (c-kit+/Sca-1+) cells in 
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blood and lungs of mice injected with Eo771 and 4T1 cells. (a-f) C57Bl/6 mice were injected into 
the mfp with wtEo771, pLKO, shLOXL2 and shE47 cells (a, b, d, e) or pLKO, shE47-416#4 (shE47) 
and shE47-416#4 cells transfected with control pcDNA3 or LOXL2-HA (c, f). Blood (a, d) and lungs 
(b, c, e, f) were analyzed at 15 dpi, compared to not injected (NI) mice. n=3-6 mice/group. (g-n) 
Balb/C mice were injected into the mfp with 4T1pLKO cells and after silencing for E47 (sh414 and 
sh416 pools) (g, h, k, l) or 4T1 cells transfected with control pcDNA3 or LOXL2-HA (i, j, m, n); blood 
(g, i, k, m) and lungs (h, j, l, n) were analyzed at 21 dpi. n=3-5 mice/group. Results represent the 
mean +/-SD of one or two independent experiments. *p<0.05, **0.001<p<0.005, ***p<0.001, 
ns=not significant. 
 
Figure 6: LOXL2 and E47 regulate the expression of fibronectin and LOX members. qPCR analysis 
of E47, Fibronectin (FN) and LOX members in primary tumors (a) and lungs (b-d) of C57Bl/6j (a-c) 
and Balb/C (d) mice injected into the mfp with (a, b) Eo771pLKO, shLOXL2 (clones #3 and #8) or 
shE47 (414pool and clone 416#4) cells, and (c) Eo771pLKO, shE47-416#4, and shE47-416#4 cells 
transfected with control pcDNA3 or LOXL2-HA at 15 dpi;  (d) lungs from Balcb/C mice injected 
with 4T1 cells transfected with control pcDNA3 or LOXL2-HA at 21 dpi. n=3-6 mice/group. Results 
represent the mean +/-SD *p<0.05, **0.001<p<0.005, ***p<0.001, ns=not significant. 
 
Figure 7: LOXL2 and E47 regulate the expression of cytokines involved in pre-metastatic niche 
formation. (a) Cytokine array incubated with conditioned media from Eo771pLKO, shLOXL2 (clone 
#3) and shE47 (414pool) cells. Factors decreased in both shLOXL2 and shE47 cells are indicated by 
black boxes (A6: ANG-1; C4: GM-CSF). (b-e) qPCR of GM-CSF, TGFβ, TNFα, TEN-C, ANG-1, S100A8 
and S100A9 in Eo771shpLKO, shLOXL2 or shE47 cells in culture (b), primary tumors (c) and/or 
lungs (d, e) of C57Bl/6 mice injected into the mfp with the indicated Eo771 cells at 15 dpi. (f) qPCR 
of the indicated cytokines in lungs from BalB/C mice injected with 4T1 cells transfected with 
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control pcDNA3 and LOXL2-HA at 21 dpi. n=3-6 mice/group. Data show the mean +/-SD. *p<0.05, 
**0.001<p<0.005, ***p<0.001, ns=not significant. (g-j) Activity of the mouse TNFα (g) and GM-
CSF (i) promoters in the indicated Eo771 cell lines in the absence or presence of 100 nM PMA. 
Activity of the mouse TNFα (h) and GM-CSF (j) promoters in Eo771-shpLKO cells in the presence 
the indicated amounts (ng) of pcDNA3-E47 and/or pcDNA3-LOXL2. RLU activity was normalized to 
pLKO cells (g, i) or in the presence of pcDNA3 vector (h, j). Data represent the mean +/- SD of six 
(g, i) and two (h, j) independent experiments performed in triplicate samples. *p<0.05, 
**0.001<p<0.005, ***p<0.001, ns=not significant.  
 
Figure 8: LOXL2 and E47 cell autonomous action on metastasis and dependence of fibronectin 
and GM-CSF expression. (a) and (b) Pre-conditioning of the metastatic niche by mfp injection of 
C57Bl/6J mice with unlabeled parental Eo771 cells; 10 days later mice were injected with 
Eo771pLKO- shE47- and shLOXL2-mCherryLuc cells and sacrificed 15 days later. Lung 
bioluminescence (a) and quantication by photon flux (b). n=5 mice/group. (c-f) Eo771shControl 
cells or interfered for fibronectin (shFN) (c) were mfp injected in C57Bl/6 mice and lung metastasis 
assessed by biolumiscence (d) and quantification of photon flux (e) at 24 dpi; (f) qPCR of GM-CSF 
and TNFα in lungs from mice injected with Eo771-PLKO and shFN cells. n=6 mice/group. (g-l) GM-
CSF was silenced in Eo771 cells (g) and mfp injected in parallel to pLKO control cells, in C57Bl/6 
mice. Bioluminescence images (h), tumor growth (i) and representative histological lung sections 
(j) at 15 dpi; asterisks in (j) indicate metastasis foci; (k) and (l) qPCR of fibronectin and TNFα (k) 
and FACS analyses of BMPC and myeloid populations (l) in lungs from Eo771pLKO and shGM-GSF-
injected mice at 15 dpi. n=5 mice/group. Color scales represent the photon flux (photons per 
second) emitted from the tumor region (h) or dissected lungs (a, d). Data in (b, c, e, f, g, i, k, l) 
represent the mean+/-SD. *p<0.05, **0.001<p<0.005, ***p<0.001, ns=not significant. 
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